Articles tagged with Microbicides
Researchers will study anal intercourse, rectal microbicides, and social networks to better understand HIV transmission. The findings will contribute to the development of prevention technologies that can be used by those engaging in anal intercourse.
Researchers at the University of Utah have developed a new vaginal gel that turns into a gel-like coating when inserted, releasing an antiviral drug when exposed to semen. The 'molecular condom' has potential as a daily or monthly prevention method for AIDS, with hopes of being up to 90% effective.
The National Institutes of Health has awarded a $4.5-million supplemental grant to UCLA's Center for HIV Prevention and Research to develop microbicides combatting HIV transmission. This funding will support collaborative work with Johns Hopkins University, University of Pittsburgh, and CONRAD.
Duke University researchers developed a computer model to predict the effectiveness of various microbicidal recipes in destroying HIV before it reaches body tissues. The study found that a thin coating of microbicide delivered to the vagina can significantly reduce HIV transmission.
Health development agencies contribute to insufficient public health budgets by requiring host countries to fund interventions sustainably. Public health budgets increase with stronger national and international financial commitments, improving healthcare capacity within host countries.
The Ptolemy Project provides electronic health information access to African surgeons, helping them deal with regional health problems. Patient navigators also aid under-served populations in accessing cancer care and services, reducing disparities. Researchers debate providing antiretroviral therapy to HIV-infected trial participants.
The University of Pittsburgh-affiliated Magee-Womens Research Institute has been selected to lead international HIV/AIDS prevention and treatment efforts. The institute will focus on developing microbicides to prevent HIV transmission, particularly among women and their partners.
Researchers found that combination of three microbicide gels provided protection against HIV-like virus in 20 out of 20 monkeys, with all three monkeys remaining virus-free. The study's findings are encouraging for the development of a microbicide for use in women.
A recent study by Tulane University has shown that vaginal gels containing microbicides can effectively prevent HIV transmission in monkeys. The researchers tested three compounds, which were found to be effective when used alone or in combination, with minimal side effects.
Dr. Henry Gabelnick, a renowned expert in reproductive health and microbicide development, has been awarded the lifetime achievement award by International Conference on AIDS India. The award recognizes his significant contributions to the field, including the development of Ushercell, a microbicide consisting of cellulose sulfate.
The new partnership between NIAID and IPM aims to accelerate the development of effective microbicides, with a focus on enhancing formulation optimization, process development, and scale-up for manufacture. Large-scale effectiveness trials of five candidate microbicides are currently underway.
CONRAD will conduct two Phase III clinical trials in India and four African countries to test a vaginal microbicide candidate, Ushercell, developed by CONRAD in collaboration with Polydex Pharmaceuticals. The goal is to determine its effectiveness in preventing HIV transmission.
The Alliance for Microbicide Development and the Global Campaign for Microbicides will receive grants to support science and policy research, public education, and advocacy. The funding will help develop evidence-based policies for microbicide R&D and investments.
A large-scale trial is underway to test two topical microbicides, PRO 2000 and BufferGel, for preventing HIV and other STIs. The study aims to evaluate the safety and effectiveness of these microbicides, which could provide a valuable woman-controlled means of slowing the pace of the HIV/AIDS epidemic.
The Emory Vaccine Center's Hope Clinic will conduct clinical trials for topical vaginal microbicide gels to prevent HIV transmission, particularly among women in Atlanta and worldwide. The trials aim to test the safety and acceptability of two different gel formulations on healthy and high-risk individuals.